Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-K/A
Source: 0001731122-25-000252
Chunk: 162

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-K/A
Chunk 162
---

to purchase 369,500 shares of Common Stock to employees with a three-year vesting period during the year June 30, 2024 under the 2019
and 2023 Plan. For the year ended June 30, 2023, the Company granted options to purchase 193,000 shares to employees with a three-year
vesting period under the 2019 Plan.

During the year ended June 30, 2024 and 2023, the Company granted options to purchase zero 0and 184,800, respectively, and zero 0and 18,960forfeited shares of Common stock to employees with a six-month vesting period, respectively under the 2019 Plan.

During the year ended June 30, 2024 and 2023, the Company granted options to purchase zero 0and 73,200issued and 0 12,640forfeited, and 65,000shares of Common stock, respectively, to employees with a one-year vesting period, respectively under the 2019 Plan.

During the years ended June 30,
2024 and 2023, the Company granted options to purchase 424,412 and 355,359 shares, respectively, to the Board of Directors and Scientific
Advisory Board Members with a one-year vesting period, under the 2019 and 2023 Plan.

During the years ended June
30, 2024 and 2023, the Company granted options to purchase 329,729
and zero 0 shares, respectively, to the Board of Directors and Scientific Advisory Board Members with immediate vesting, under the
2019 and 2023 Plan.

During the years ended June 30,
2024, and 2023, the Company granted options to purchase 10,000 and 75,000 shares, respectively, for consulting services with a one-year
vesting period, under the 2019 and 2023 Plan.

F-30

All of the above options are exercisable
at the market price of the Company’s Common Stock on the date of the grant. On February 13, 2024, the Company repriced 3,849,931
eligible employee and consultant options from the original issued exercise price to a new exercise price of $1.92 per share, the closing
price of the Company’s Common Stock on February 13, 2024. The Company recognized stock-based compensation expense related to the
repricing